TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of “Hold” from Brokerages

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has been given a consensus recommendation of “Hold” by the five brokerages that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $11.00.

Several research firms have recently weighed in on TLSI. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a report on Monday, December 29th. Zacks Research upgraded shares of TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, December 16th. Canaccord Genuity Group increased their price target on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Finally, Wall Street Zen lowered shares of TriSalus Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, January 17th.

TriSalus Life Sciences Stock Performance

Shares of TLSI stock opened at $5.49 on Friday. The stock’s 50-day moving average is $6.32 and its two-hundred day moving average is $5.25. TriSalus Life Sciences has a 1 year low of $3.42 and a 1 year high of $7.95. The firm has a market cap of $274.28 million, a price-to-earnings ratio of -2.72 and a beta of 0.43.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its earnings results on Thursday, November 13th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.79). The firm had revenue of $11.57 million during the quarter, compared to analyst estimates of $11.76 million. As a group, research analysts predict that TriSalus Life Sciences will post -1.55 EPS for the current year.

Institutional Trading of TriSalus Life Sciences

Hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. purchased a new position in shares of TriSalus Life Sciences in the 1st quarter valued at approximately $187,000. Geode Capital Management LLC raised its stake in shares of TriSalus Life Sciences by 107.4% during the second quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock worth $2,480,000 after purchasing an additional 235,627 shares during the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of TriSalus Life Sciences during the second quarter worth $29,000. JPMorgan Chase & Co. grew its position in TriSalus Life Sciences by 35,804.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after buying an additional 7,519 shares during the last quarter. Finally, Connective Capital Management LLC increased its stake in TriSalus Life Sciences by 12.8% in the 2nd quarter. Connective Capital Management LLC now owns 32,796 shares of the company’s stock valued at $179,000 after buying an additional 3,717 shares during the period. 2.58% of the stock is owned by institutional investors and hedge funds.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.